Federica Corallini
Overview
Explore the profile of Federica Corallini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
771
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Voltan R, Secchiero P, Corallini F, Zauli G
Mol Carcinog
. 2012 Nov;
53(6):498-504.
PMID: 23192887
The small molecule inhibitor of the MDM2/p53 interaction Nutlin-3 is a promising anti-cancer agent, which exhibits activity against a variety of cancers, including acute myeloid leukemia (AML). Previous studies have...
2.
Corallini F, Celeghini C, Rimondi E, di Iasio M, Gonelli A, Secchiero P, et al.
J Cell Physiol
. 2011 Jun;
226(9):2279-86.
PMID: 21660951
The soluble member of the TNF-R superfamily osteoprotegerin (OPG) is abundantly released under basal conditions by both mesenchymal stem cells (MSC) and fibroblasts and by endothelial cells upon stimulation with...
3.
Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, et al.
Atherosclerosis
. 2010 Dec;
215(2):452-8.
PMID: 21122855
Objective: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exhibits biological activity on vascular cells in vitro. Rapid variation of circulating TRAIL levels occurs during acute coronary ischemia, suggesting that biological pathways...
4.
Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, et al.
Invest New Drugs
. 2010 Oct;
30(1):417-22.
PMID: 20953816
The multi-kinase inhibitor dasatinib induced a variable but significant decrease of viability in both p53(wild-type) (EHEB, JVM-2, JVM-3) and p53(mutated) (MEC-1, MEC-2, BJAB) prolymphocytic B leukemic cells, due to a...
5.
Toffoli B, Bernardi S, Candido R, Sabato N, Carretta R, Corallini F, et al.
Mol Cell Endocrinol
. 2010 Sep;
331(1):136-42.
PMID: 20832449
Although serum osteoprotegerin (OPG) is significantly increased in diabetic subjects, its potential role in beta cell dysfunction has not been investigated. This study aimed to assess the effect of full-length...
6.
Secchiero P, Corallini F, Zavan B, Tripodo C, Vindigni V, Zauli G
Invest New Drugs
. 2010 Sep;
30(2):803-7.
PMID: 20827501
A disseminated model of non-Hodgkin's lymphoma with prevalent liver metastasis was generated by intraperitoneal (i.p.) injection of EBV(+) B lymphoblastoid SKW6.4 in nude-SCID mice. The survival of SKW6.4 xenografts (median...
7.
Zauli G, Corallini F, Zorzet S, Grill V, Marzari R, Secchiero P
Invest New Drugs
. 2010 Aug;
30(1):405-7.
PMID: 20714918
A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) was characterized for anti-lymphoma activity in vivo. For this purpose, a disseminated lymphoma model was generated by...
8.
Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, et al.
PLoS One
. 2010 Jun;
5(6):e11140.
PMID: 20585401
Background: Although multimodality treatment can induce high rate of remission in many subtypes of non-Hodgkin's lymphoma (NHL), significant proportions of patients relapse with incurable disease. The effect of human bone...
9.
Secchiero P, Corallini F, Castellino G, Bortoluzzi A, Caruso L, Bugatti S, et al.
J Rheumatol
. 2010 May;
37(7):1461-6.
PMID: 20472926
Objective: To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients...
10.
Corallini F, Secchiero P, Castellino G, Montecucco M, Trotta F, Zauli G
Ann Rheum Dis
. 2010 May;
69(9):1733-4.
PMID: 20447952
No abstract available.